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Sexual Dysfunction in Patients 
with Systemic Sclerosis
Barbora Heřmánková
Abstract
Systemic sclerosis (SSc) may affect all aspects of life including sexual function. 
Although sexual dysfunction is a neglected area of quality of life in patients with 
SSc, it turns out that it is an important issue for both men and women character-
ized by high prevalence. The etiology of sexual dysfunction in systemic sclerosis 
is multifactorial and includes factors associated with both physical and emotional 
(psychological) status. The most common physical problems in women are vaginal 
dryness, dyspareunia, and vaginal tightness. Erectile dysfunction is not only a 
frequent but also often underestimated clinical symptom in men with SSc. The 
incidence of erectile dysfunction in patients with SSc ranged from 12 to 81% in dif-
ferent studies. The main psychological factors that may affect sexuality are depres-
sion, fear, and changes in the appearance of the face and body that usually leads to 
impaired self-esteem. This chapter is a review about the impact of systemic sclerosis 
on sexual functioning.
Keywords: systemic sclerosis, sexual functioning, female sexual dysfunction,  
erectile dysfunction
1. Introduction
Systemic sclerosis is a chronic rheumatic autoimmune disease characterized 
by abnormal fibrotic processes, microvascular damage, and excessive deposition 
of collagen into connective tissues. The vascular alterations and immunological 
activation lead to progressive fibrosis of multiple organ systems including the 
skin, the gastrointestinal tract, kidneys, and the lungs. Disease-associated changes 
can have a negative impact on sexual functioning [1, 2]. Generally, sexuality in 
systemic sclerosis has been a neglected area so far, especially female sexual dysfunc-
tion. Impaired sexual functioning in women was probably less studied due to the 
complexity and multifactorial nature of female sexual response. A little bit more 
attention was paid to erectile dysfunction, where etiology is more pronounced even 
though women are affected by this disease more often [3–5]. The etiology of sexual 
dysfunctions in systemic sclerosis is not well known; the causes are multifactorial 
and are related to both the disease symptoms and the therapy. The most common 
physical problems associated with female sexual dysfunction include vaginal dry-
ness, dyspareunia, vaginal tightness, Raynaud’s phenomenon, fatigue, generalized 
pain, muscle weakness, joint contractures, heartburn, and dyspnea. Presence of 
depression, fear, changes in face and body appearance, and lack of self-esteem are 
the psychological aspects, which can play a key role in the pathogenesis of sexual 
dysfunction in systemic sclerosis patients [6]. The etiology of erectile dysfunction 
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is a little bit more understood. It is considered to be a result of microangiopathic 
changes. Due to corporal fibrosis and myointimal proliferation, the blood flow in 
the penile arteries is reduced.
Several studies have suggested that sexual dysfunction is a widespread problem 
in both men and women with SSc. It is more prevalent than in general population 
and other chronic diseases [7]. The most common symptoms of female sexual dys-
function are vaginal tightness, dryness, and dyspareunia [7, 8]. More severe sexual 
dysfunction is usually associated with depression symptoms, aging, and functional 
impairment [2, 9, 10]. The prevalence of erectile dysfunction is about 80% [11–13]. 
In women, more than half of the SSc patients experience some sexual problems [7, 8].  
The management of erectile dysfunction has been more studied compared to female 
sexual dysfunction treatment. However, the number of publications regarding 
the efficacy of erectile dysfunction treatment in SSc patients is still very limited 
and further research is needed. The treatment of female sexual dysfunction in SSc 
women has not been paid much attention so far. There are only general recommen-
dations available.
2. Definition and classification of sexual dysfunction
In order to better understand why and how systemic sclerosis may affect sexual 
functioning, there is an overview of sexual response models, developed over the 
past few years, which led to the current diagnostic and classification criteria for 
sexual dysfunction. The first model of female sexual response was described by 
Masters and Johnson in 1966. They published that a normal female sexual response 
consists of four consecutive phases including desire, plateau phase, orgasm, and 
resolution. It was supposed that in both women and men, the sexual response is 
commenced by desire which is influenced by the activity of two brain centers—
dopamine sensitive excitatory center and serotonin sensitive inhibitory center. 
These centers send a signal going through the descendent nervous system into the 
spinal cord from where the genital sexual reaction is triggered. The arousal phase is 
mediated by the parasympathetic nervous system, which leads to vascular and geni-
tal changes such as enlargement of the clitoris, dilatation of perivaginal arterioles, 
and lubrication and expansion of two-thirds of the vagina. The following level of 
excitement is referred to the plateau phase that lasts until the orgasm. The orgasm 
phase is accompanied by contractions of pelvic floor muscles, increased heart rate, 
respiratory rate, and blood pressure. After reaching orgasm, the body usually calms 
down and this phase is called the refractory or resolution phase (Figure 1) [14].
In 1979, this model was modified by Kaplan into a three-phase model, which 
consists of desire, arousal, and orgasm [15]. Based on this linear model, the diag-
nostic and classification system was developed. The World Health Organization 
International Classifications of Diseases-10 (ICD-10) and Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) by the American Psychiatric Association 
were established. The ICD-10 focused on how physical factors influenced sexual 
response, whereas DSM-IV classification emphasized more emotional and psycho-
logical aspects of female sexual dysfunction. Because both approaches followed 
the linear model of sexual response, which was later criticized for not taking into 
consideration the complexity of female sexual response, the new classification was 
needed [16].
In 1998, the Sexual Function Health Council of the American Foundation for 
Urologic Disease (AFUD) convened an interdisciplinary congress, which was 
attended by 19 experts on female sexual dysfunction selected from five countries. 
The aim was to develop a consensual definition and classification based on the 
3Sexual Dysfunction in Patients with Systemic Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.86219
ICD-10 and DSM-IV. The new developed classification has been extended to 
include psychogenic and organic causes of desire, arousal, orgasm, and sexual pain 
disorders. An essential point of this classification is the personal distress criterion 
considering sexual complaint as a disorder only if it causes a subjective feeling of 
distress [17].
Further research has shown that the model of female sexual response is still 
incomplete and that many aspects affecting women’s sexual function have been 
omitted. Studies reported that women often describe overlapping phases of 
sexual response in variable sequences. For instance, the unfounded assumption 
that desire always precedes arousal has been mistaken, and based on the women 
self-report and research data, it was proven that arousal and desire co-occur and 
reinforce each other. It was also found that motivation for sexual activity is much 
more complex than the mere presence of sexual desire defined as thinking or 
fantasizing about sex. Women in different surveys cited that increased desire for 
sexual activity may be caused by the emotional closeness of a partner or intimacy 
that increases female well-being and self-image, which may include the sense of 
feeling attractive, appreciated, loved, or desired. If enough appropriate sexual 
stimulation is provided, enough time and intimacy are available, the woman’s 
enjoyment and excitement can be intensified. The type of stimulation, time 
needed, and interpersonal context are highly individual. Moreover, spontaneous 
desire can be affected by the menstrual cycle, which usually decreases with age 
and grows with a new relationship. These new findings have surpassed the origi-
nal hypothesis that women’s sexual response must always begin with sexual desire 
(thoughts and fantasies) and its absence is the result of a disorder. In addition, it 
was confirmed that, unlike men, there is no correlation between female subjective 
excitement and genital congestion. Subjective excitement could be influenced 
by interpersonal relationships, contextual factors, privacy, appropriateness, 
general emotional status, emotional relationships, biological factors, presence of 
depression, the influence of hormones (dopamine, testosterone), and others. In 
2003, therefore, a revision of the current definition was done. The International 
Definitions Committee consisting of 13 experts from seven countries convened 
and proposed new definitions, which take into account new findings in the field 
of female sexual response [18–20].
Figure 1. 
The four-phase model of female sexual response cycle; BP = blood pressure, HR = heart rate, and 
RR = respiratory rate. Modified according to [14].
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Current definition was again revised in 2010 by the International Consensus 
of Sexual Medicine, where the movement away from the nonoverlapping linear 
model toward a more circular model depicting the variety of triggers of women’s 
desire was accepted. It was emphasized that innate sexual fantasies and thoughts are 
not necessary for healthy sexual functioning and that desire is the result of sexual 
incentive that may be physically or subjectively perceived. Based on the previous 
findings, the arousal disorder was reclassified into subjective arousal disorder, 
genital arousal disorder, combined genital and subjective arousal disorder, and per-
sistent genital arousal disorder. In May 2013, DSM-V was released, which also takes 
the focus away from the four-phase model, removed the sexual aversion disorder 
and merged vaginismus and dyspareunia into a new genito-pelvic pain/penetration 
disorder. It was finally noted that sexual dysfunction is a result of both psychologi-
cal and biological and many other contributing factors [15, 21]. In 2015, the Fourth 
International Consultation on Sexual Medicine presented the new set of definitions 
of all forms of sexual dysfunction in women and men, which was based on ICD-10 
and DSM-V (Figure 2) [22].
The newest changes in nomenclature of female sexual dysfunction came in May 
2018, when the World Health Organization developed the eleventh revision of the 
International Classification of Diseases and Related Health Problems (ICD-11). 
The ICD-10 classification of sexual dysfunctions was separated to two main groups: 
“organic” and “nonorganic” conditions. The nonorganic sexual diseases were 
classified as mental and behavioral disorders and organic belonged to diseases of 
the genitourinary system chapter. However, since ICD-10 definition, lots of evi-
dences have been accumulated regarding the causes of sexual dysfunction, which 
often involve a combination of physical and psychological factors. The ICD-10 
Figure 2. 
Nonlinear model of female sexual response cycle. The initial stage of female sexual response is sexual neutrality, 
but with positive motivation (left). The reasons why a woman is willing to initiate or agree to sexual activity 
can be that she wants to feel loved, share physical pleasure or be emotionally closer to her partner, please her 
partner, or she wants to increase her own satisfaction. Stimuli for sexual activity are being processed in the 
woman’s mind, influenced by biological and psychological factors, and result in subjective sexual arousal. If 
sexual stimuli last sufficiently long, sexual arousal and enjoyment will intensify, and it can trigger a desire for 
further sexual activity. It is important to note that desire appears at this point, not in the initial phase. When 
the stimulation continues and no negatives outcomes are involved, the process results in sexual satisfaction (with 
or without orgasm). Modified according to [23].
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classification was therefore not consistent with clinical approaches in sexual health. 
ICD-11 diagnostic guidelines organize sexual dysfunctions into four main groups:
1. sexual desire and arousal dysfunctions;
2. orgasmic dysfunctions;
3. ejaculatory dysfunctions; and
4. other specified sexual dysfunctions.
Moreover, a separate grouping of sexual pain disorders has been established. 
Where possible, categories in this new classification of sexual dysfunctions apply 
to both men and women even though the differences in sexual response are known. 
On the other hand, the neural pathways and neurotransmitters mediating sexual 
response are the same for both men and women. Separate sexual dysfunction 
categories are provided where clinical manifestations differ [24].
The overview of current diagnostic criteria of sexual dysfunctions is presented 
below in Table 1. The present definition according the WHO ICD-11 is: “Sexual 
Dysfunctions are syndromes that comprise the various ways in which adult people 
may have difficulty experiencing personally satisfying, noncoercive sexual activi-
ties. Sexual response is a complex interaction of psychological, interpersonal, 
social, cultural and physiological processes and one or more of these factors may 
affect any stage of the sexual response. In order to be considered a sexual dysfunc-
tion, the dysfunction must: (1) occur frequently, although it may be absent on some 
occasions; (2) have been present for at least several months; and (3) be associated 
with clinically significant distress” [25].
ICD-11 (2018) DSM-5 (2013)
Chapter: conditions related to sexual health
Grouping: sexual dysfunctions Grouping: sexual dysfunctions
Category: hypoactive sexual desire 
dysfunction
Category: female sexual interest/arousal disorder; male hypoactive 
sexual desire disorder
Category: sexual arousal dysfunction Category: female sexual interest/arousal disorder
Category: orgasmic dysfunction Category: female orgasmic disorder
Category: ejaculatory dysfunction Category: erectile disorder
Subcategory: male early ejaculation Category: premature (early) ejaculation
Subcategory: male delayed 
ejaculation
Category: delayed ejaculation
Category: other specified sexual 
dysfunction
Category: other specified sexual dysfunction
Category: unspecified sexual 
dysfunction
Category: unspecified sexual dysfunction
Grouping: sexual pain disorders
Category: sexual pain-penetration 
disorder
Category: genito-pelvic pain/ penetration disorder
Table 1. 
The eleventh revision of the International Classification of Diseases and Related Health Problems (ICD-11) 
and Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Adapted from [25, 26].
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3. Sexual functioning in women with systemic sclerosis
Persons with systemic sclerosis can experience a variety of symptoms that may 
affect all aspects of life, including sexual functions. The exact etiopathogenesis of 
sexual dysfunctions in systemic sclerosis is not well known; the causes are multi-
factorial and are related to both the disease symptoms and the therapy. Medical, 
pathophysiological, psychological, and social components may be involved in 
sexual dysfunction. Both physical and psychological problems arising from disease-
related condition contribute to partnership difficulties, less active and less enjoy-
able sexual life [3, 27, 28].
The most common physical symptom is skin tightness. Due to skin tightness, 
the fingers becomes fixed in bent position, which could interfere with sexual 
foreplay, touch, and masturbation. If skin tightening causes the mouth to shrink, 
kissing or oral sex could become difficult. Sometimes the skin become stiffer 
around the vaginal introitus, which often leads to painful penetration, and changes 
in the vaginal mucosae causing lubrication disorder contribute to this [27, 29, 30]. 
Specifically, 56% of SSc female patients reported painful penetration during the 
intercourse [31]. The sexual difficulties such as vaginal tightness, dryness, and 
dyspareunia were reported by more than half of systemic sclerosis female patients 
[7, 8]. It was also published that vaginal tightness (71%), dyspareunia (56%), and 
ulceration (23%) were the most common symptoms of sexual dysfunction observed 
in 60 women with systemic sclerosis [31]. These genital tract abnormalities could be 
associated with a decrease in number and intensity of orgasm, which are also often 
observed in SSc individuals [32].
A majority of the systemic sclerosis patients experience Raynaud’s phenomenon, 
which can affect not only fingers and toes but also tongue and nipples. This is 
another reason, why the cuddling, foreplay, and oral sex could become uncom-
fortable and unpleasant [27]. In addition, a lot of patients suffer from secondary 
Sjögren’s syndrome characterized by drying of oral, nasal, ocular, and vaginal 
mucosae. The prevalence of Sjögren’s syndrome in systemic sclerosis ranged in 
different studies from 20 to 69% depending on the criteria used and sample size. 
In Saad’s study, 37% from 83 systemic sclerosis female patients reported Sjögren’s 
syndrome, 56% of them had impaired sexual function, and vaginal dryness was the 
most presented symptom [29].
Another disease-related problem that impedes sexual activity is the affection 
of musculoskeletal system. The presence of joint contractures, stiffness, or pain 
leads to limited range of motion and it could restrict the ability to engage in sexual 
activities. Other aspects that reduced exercise capacity are muscle weakness and 
fatigue. It can be difficult to become sexually aroused when extremely tired. The 
consequence of skin thickening and other physical changes is the impaired body 
image, self-esteem, and sexuality. However, it has been also reported that body 
image dissatisfaction does not correlate with reduced sexual function [30]. In a 
different study, the major reasons for decreased sexual activity in married women 
with SSc were fatigue, altered body image, and pain [2]. Regarding psychological 
factors, depression is another often presented symptom that has been significantly 
associated with a sexual function disorder [8].
There are a few more causes that could lead to less active sexual life in SSc 
patients. For instance, in rare cases, the fibrotic process of visceral vessels leads to 
renal impairment that may have an impact on sexual desire and orgasm. It is usually 
the medication used to treat kidney problems rather than the problems themselves. 
Also, gastrointestinal problems such as heartburn or chronic diarrhea may disrupt 
sexual activities [7].
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To sum up, existing studies of sexual function among women with SSc have 
concluded that sexual dysfunction is common in comparison to the general popula-
tion. It was even showed a significantly greater decrease in orgasm and its intensity 
in SSc female patients compared to other systemic rheumatic diseases—rheumatoid 
arthritis and systemic lupus erythematosus [31]. What is more, Knafo et al. [4] 
published that the prevalence of sexual dysfunction is higher in SSc than in other 
chronic diseases such as breast cancer, gynecological cancer, or HIV positivity. 
On the other hand, Impens et al. [33] maintain that SSc women remain sexually 
active despite the psychological and physical difficulties caused by the disease. In 
this study, only 17% of women suffered from female sexual dysfunction primar-
ily caused by systemic scleroderma. Other reasons for sexual inactivity were the 
absence of a partner (37%), personal choice (32%), and the health status of respon-
dents’ partners (20%).
4. Diagnostic approach of female sexual dysfunction
The first step in the diagnosis of female sexual dysfunction is a detailed per-
sonal, sexual, pharmacological, and psychosocial history. Where necessary, further 
examination by a psychiatrist, gynecologist, or physiotherapist is indicated. There 
are several objective methods assessing female sexual function, such as laboratory 
tests including hormonal profile or Doppler ultrasonography. However, labora-
tory tests in clinical practice are used only as auxiliary diagnostic methods. With 
duplex Doppler ultrasonography, it is possible to display a blood flow in cavernous 
tissue vessels, which is performed either under basal conditions or during sexual 
stimulations (vibrational or audiovisual) and objectified sexual arousal reactions. 
The most commonly used physiological method for evaluating sexual response is 
vaginal photoplethysmography, which investigates vascular reactivity during sexual 
arousal. It is based on the assessment of congestion of the vaginal mucosae. Other 
methods include electromyography, measurement of changes in vaginal pressure, 
and measurement of pH [34, 35].
Another widespread screening method is the questionnaire survey. Self-report 
questionnaires have a long history of use in psychological and sociological studies 
of sexual behavior. For example, Derogatis Sexual Function Inventory is a 245-
item, multidimensional scale that evaluates a wide range of sexual behavior in 10 
separate domains. Despite the very strong psychometric properties, this scale is 
not widely used in clinical trials due to its excessive length and complexity. Instead, 
several short evaluation scales have been developed [36, 37]. Currently, the female 
sexual function index (FSFI) is the “gold standard” in assessment of female sexual 
functioning [38]. FSFI is a widely used tool that has been validated for use across 
multiple populations including women of various age groups, in various health 
problems and sexual dysfunctions. It has been developed as a simple multidimen-
sional self-assessment tool for assessing the key domains of female sexual function. 
The questionnaire consists of 19 items that evaluate sexual function over the last 
4 weeks in six domains: sexual desire, sexual arousal, lubrication, orgasm, satisfac-
tion, and pain [39]. Since the first validation study, it has been translated into more 
than 20 languages and validated in over 30 countries [40, 41].
It has to be noted that both objective methods and questionnaire screenings have 
their limitations. The main disadvantage of objective methods is the absence of an 
intimate condition that can play a key role in the female subjective arousal. Basson 
et al. published that intimacy and desire are essential to women’s sexual activity. 
Raina et al. reported that intimacy leads to emotional arousal of a woman, followed 
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by sexual desire and physical arousal that result in sexual satisfaction. These 
findings suggest that the presence of intimacy can be crucial in examining sexual 
arousal, and its absence can lead to a lack of emotional excitement and consequently 
to incomplete sexual responses [35, 42, 43]. On the contrary, the questionnaires 
are filled in private and evaluate women’s real sexual experiences. Moreover, this 
method is not time-consuming and costly. However, as with any brief self-report 
scale of a complex psychophysiological construct, the questionnaire assessment 
has notable practical and theoretical limitations. Self-reported screening does not 
provide objective information but only patient’s subjective perception.
In terms of FSFI, its drawback is the assessment of sexual activity in the past 
4 weeks. Of course, there are number of reasons why women may be sexually 
inactive during a 4-week period and it does not necessarily imply significant sexual 
dysfunction. For example, the absence of sexual partner is a very common reason, 
why patients are not sexually active. Specifically, the FSFI questionnaire contains 15 
questions, which could be answered “No sexual activity” or “Did not attempt inter-
course.” Both possible responses are scored as zero that could become problematic 
when lower scores indicate severer sexual dysfunction. In that case, the FSFI could 
produce biased results. Other inaccurate data may be the result of relatively vague 
terminology. A problematic issue seems to be to define and measure sexual desire 
and subjective sexual arousal. Studies suggest that women often have difficulty 
distinguishing desire and arousal in their sexual experience. Another drawback of 
the FSFI questionnaire is that questions in orgasm subscale are basically focused on 
the orgasmic function associated with penile-vaginal contact. In fact, the vagina 
is primarily a reproductive organ with little sensitivity, and clitoral stimulation is 
more important for female orgasm. Therefore, achieving orgasm should be judged 
more in conjunction with masturbation or oral sex than sexual intercourse [38, 44].
5. The use of the FSFI questionnaire in systemic sclerosis patients
The FSFI is also the most common questionnaire evaluating sexual function in 
women with systemic sclerosis. It has been used by an Italian team to evaluate the 
prevalence of sexual dysfunction in 46 women with SSc. The second purpose of this 
trial was to investigate the association with sociodemographic, physical, psycho-
logical, and disease-related variables. Compared to healthy controls, only the FSFI 
desire subscale score was significantly lower. The overall score did not substantially 
differ from healthy controls. The association with health status, functional ability, 
mouth affection, hand disability, and presence of depression was reported [10]. 
A very similar study has been conducted in the Netherlands. The FSFI was used 
to assess the sexual function of 69 SSc women aged 18–60 years. It was that the 
FSFI total score and the subscale scores for lubrication, orgasm, arousal, and pain 
were significantly lower in comparison with healthy population in the same age. 
Impaired sexual functioning and sexual distress were associated with marital dis-
tress and depressive symptoms [9]. Levis et al. first detected women with SSc who 
had engaged in sexual activities with their partner in the past 4 weeks, and then 
only sexually active patients completed a 9-item version of the FSFI. The aim of this 
Canadian cross-sectional multicenter study was to evaluate sociodemographic and 
clinical variables that distinguish sexually active from inactive patients and identify 
the source of pain during and after sexual activity in sexually active patients. The 
results showed that in total only 17% of 547 women were sexually active without 
sexual disorder [45]. The same group of scientists in different project used a short-
ened version of FSFI to compare sexual activity and impairment rates of women 
with systemic sclerosis to general population data. Among women with SSc, 296 of 
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730 (41%) were sexually active and 181 (61%) of sexually active patients reported 
sexual dysfunction. It means that only 115 of 730 (16%) patients engaged in sexual 
activities without impairment. It was also confirmed that SSc patients are signifi-
cantly less likely to be sexually active and more likely to be sexually impaired than 
the general population of women [46]. Severe sexual dysfunction was also observed 
in married women with systemic sclerosis. About 8 out of 10 women achieved low 
scores in the FSFI questionnaire assessed, and all the subscales were affected in this 
study. The reasons why patients reported decrease in the frequency of intercourse 
since the onset of their disease and a diminished desire for a sexual relationship 
were fatigue, altered body image, and pain [2].
6. Treatment and recommendation for female sexual dysfunction
The management of female sexual dysfunction in the general population is 
based on the understanding of the basic physiology of female sexual response. 
Currently, several approaches of female sexual function treatment are available. It 
is known that some antidepressants can cause sexual dysfunction as a side effect. 
Antidepressants, such as SSRIs, are commonly associated with hypoactive sexual 
desire disorder (HSDD) and they have to be eliminated or dosed at lower levels. 
In women with major and disabling mood disorders, the adjustment of antide-
pressants requires a continuous collaboration with the prescribing psychiatrist, 
because dosage adjustments of antidepressants must be done very gradually [47]. 
Bupropion, buspirone, mirtazapine, vortioxetine, and vilazodone have been 
found to have lower rates of antidepressant-induced sexual dysfunction than other 
antidepressants, and they can be a suitable medication options for the treatment of 
depression [48–50].
Another option, primarily used in menopausal women, is hormonal therapy. 
Estrogen therapy may be used to increase clitoral sensitivity and libido and to 
reduce pain during and after sexual intercourse. In women with menopause-related 
sexual dysfunction that have estrogen treatment experience improved sexual desire, 
vaginal atrophy and vaginal dryness [49]. Transdermal estradiol has been found to 
be a preferred therapy for depleted estrogen. It is considered as the most effective 
therapy available for reducing vasomotor symptoms and associated menopausal 
symptoms with minimal adverse effects. Intravaginal estrogens combined with 
mechanical dilatations are also highly effective for treatment of vaginal atrophy 
[47]. Testosterone replacement therapy may also be considered to increase sexual 
desire and libido. Several high-quality sources documenting that transdermal 
testosterone is effective in restoring sexual desire are available [47]. Intramuscular 
testosterone combined with estradiol in postmenopausal women had a positive 
impact on sexual desire, arousal, and frequency of sexual fantasies compared with 
women without testosterone treatment [51].
Flibanserin is the first nonhormonal treatment for female sexual dysfunction to 
be approved by the Food and Drug Administration (FDA). The approval, in August 
2015, occurred fully 18 years after the approval of sildenafil, the first treatment 
for erectile dysfunction. Flibanserin is a 5-HT 1A agonist and 5-HT 2A antagonist 
and is indicated for acquired hypo-active sexual desire disorder in premenopausal 
women. It is strongly recommended to avoid consumption of alcohol while using 
flibanserin treatment, because several serious adverse events were found: dizziness, 
loss of consciousness, hypotension, and circulatory collapse [49]. Another drug 
approved by the FDA is ospemifene, which is indicated in treatment of dyspareunia 
in postmenopausal women. It is a selective estrogen receptor modulator that can 
be prescribed when hormone replacement therapies fail. The daily dose of 60 mg 
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of ospemifene has been found to be effective and tolerable for postmenopausal 
women with vaginal dryness and atrophy [52, 53]. To improve sexual functioning 
in domains of arousal, orgasm, and satisfaction, bupropion can be used, whose 
efficacy is based on the influence of dopamine and norepinephrine reuptake [54]. 
Although phosphodiesterase type 5 (PDE-5) inhibitors are mostly used in erectile 
dysfunction treatment, they can be used in women as well. Sildenafil has been 
found to significantly improve arousal, orgasm, and enjoyment in women without 
sexual dysfunction. In women with antidepressant-associated sexual dysfunction, 
sildenafil (in dose ranges of 50–100 mg) has also shown good efficacy [49].
Rehabilitation treatment can be useful in patients suffering from vaginism, 
dyspareunia, and anorgasmia due to pelvic muscle spasms. Adequate exercises 
can lead to normalization of muscle tension and relaxation [55]. Psychotherapy is 
recommended where the pathogenesis of sexual dysfunction has a psychological 
nature. Because recent studies have suggested that more severe sexual dysfunctions 
in patients with SSc are significantly associated with the presence of depression 
[2, 9, 10], the psychotherapy should be an integral part of the treatment of sexual 
dysfunction in SSc patients. In terms of sexual pain disorder, psychotherapy seems 
to be immediately helpful although objective research on the long-term efficacy of 
psychotherapy for sexual pain disorder is limited and difficult to evaluate [47].
There are some general recommendations for women with systemic sclerosis 
that may help to continue enjoying an active, fulfilling sexual life. If sexual activity 
is reduced due to pain, it can be alleviated by use of pain medication. The sexual 
activity can be scheduled for a time the pain will be at a minimum. A warm bath or 
shower before sexual activity often eases arthritic stiffness. The range of motion 
exercises before sex may help to reduce the stiffness. If the range of motion is 
limited and do not allow comfortable position, then it seems to be a good solution to 
experiment with sexual positions and try to find those that are the most suitable  
[3, 56]. If sclerosis has caused the mouth to shrink, physical therapist or occupa-
tional therapist can teach patients how to do the exercises to stretch the mouth. 
The regular stretching can improve the range of motion of the mouth and make 
kissing and oral sex more enjoyable. When fingers become fixed in a bent position, 
its possible to integrate stretching exercises as well and use the other part of hands 
(thumbs, wrists, or backs of the hands) to touch yourself or partner. An auxiliary 
material such as vibrators, creams, and lotions can also be used to enhance sexual 
activity. In order to avoid fatigue, patients with SSc may schedule their sexual activ-
ity for that part of the day when they still have enough energy, because becoming 
sexually aroused, when tired, is difficult. To prevent a Raynaud episode, it is neces-
sary to keep entire body warm. It is possible to turn up the thermostat, leave some 
clothes on, or use extra blankets. When vaginal dryness and dyspareunia occur, the 
use of vaginal moisturizers on a regular basis along with lubricants as needed for 
sexual activity is the initial step in managing these symptoms. Women can choose 
from a number of commercially available lubricants that are either water based, 
mineral or plant oil based, or silicone based [47, 55]. Dilator therapy is an another 
option that can be useful in treatment of vaginal tightness. This method offers a 
nonsurgical approach to restore vaginal capacity and elasticity and alleviate sexual 
discomfort. If the penetration is still painful, there are alternative sexual activities 
like clitoral stimulation that can be sometimes more enjoyable than intercourse. 
If there is no interest in sex, still it is possible to stay physically close by holding or 
caressing one another [3, 56].
Several options for the treatment of female sexual dysfunction in normal popu-
lation are available. The management of impaired sexuality in women with systemic 
sclerosis was less studied and the further research is strongly needed. What is essen-
tial and beneficial for the patients is the team-based model of care for management 
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of sexual dysfunction including a medical provider, physical therapist, occupational 
therapist, psychotherapist, and sex therapist [57].
7. Sexual functioning in male with systemic sclerosis
Systemic sclerosis is an autoimmune connective tissue disorder characterized 
by following typical findings: endothelial changes, microangiopathic damages, and 
progressive fibrosis. These pathological processes may affect various organs includ-
ing penile arteries leading to erectile dysfunction (ED). Male erectile dysfunction 
is defined as the consistent inability to reach and maintain an erection sufficient 
to permit satisfactory sexual performance. It is a widespread issue in men with 
systemic sclerosis. Sexual dysfunction in men has been given more attention than 
female sexual dysfunction, and the etiology is more obvious compared to women. 
Erectile dysfunction is a result of microangiopathic changes, when the blood flow 
is reduced in the small penile arteries due to corporal fibrosis and myointimal 
proliferation [5]. It was proven that damage of the penile cavernous arteries occurs 
in almost all SSc patients regardless of clinical symptoms. They are characterized by 
the presence of hyperechoic spots, suggesting fibrotic changes and low peak systolic 
velocities that are signs for vascular alterations [58].
The prevalence of erectile dysfunction in SSc patients ranged from 12 to 81% in 
different studies [28]. However, most studies agree that about 80% of SSc men are 
affected [11–13]. It was also found that ED is more prevalent in systemic sclerosis 
than other inflammatory rheumatic diseases. In a majority of men with systemic 
sclerosis, ED started to manifest after the onset of the disease. The mean duration 
from the onset of the first SSc symptom to erectile dysfunction was around 3 years 
[12]. Risk factors of erectile dysfunction such as smoking, hypertension, diabetes, 
and steroid use have been investigated. It was found that only self-reported history 
of nerve damage and diabetes are significant for predicting the likelihood of ED in 
systemic sclerosis. There are also risk factors that are presented in non-SSc men as 
well, like older age or alcohol consumption. The ED association with more severe 
diseases in terms of worse skin involvement, elevated pulmonary arterial pressures, 
presence of restrictive lung disease, and muscular and renal involvement in SSc 
patients was also confirmed [5, 12, 13, 59].
The most likely hypothesis of ED in SSc is a combination of vascular and fibrotic 
abnormalities. In men with SSc, decreased penile blood pressure, impaired peak 
systolic and diastolic blood flow in the penile arteries, and the presence of veno-
occlusive dysfunction were found. Also, a decreased penile temperature and a slow 
recovery after cold exposure were reported. A duplex sonography was conducted to 
reveal the thickening of tunica albuginea and diffuse hyperechogenic spots within 
the corpora cavernosa. All these findings point to the microangiopathic cause of ED 
in male SSc patients. This is confirmed by the fact that no carotid artery thicken-
ing has been found in SSc, which would predict atherosclerotic macroangiopathy. 
From a histological point of view, the ED cause in SSc men is the presence of 
severe corporal fibrosis, increased collagen production by penile smooth muscle 
cells, and increased accumulation of extracellular matrix. Due to these changes, 
penile hypoxia arises, which can lead to overexpression of platelet-derived growth 
factor (PDGF), transforming growth factor (TGF)-β1 and TGF-β1 receptors in 
the corpora cavernosa, which are important profibrotic regulators of collagen 
synthesis and production of extracellular matrix. In addition, endothelin (ET-1) 
is also released by penile smooth muscle cells. Thus, penile hypoxia stimulates 
penile fibrosis. Therefore, it can be assumed that once ED in patients with SSc is 
manifested (due to disease), its next mechanisms are similar to those of non-SSc 
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population. Other causes such as hormonal abnormalities or neurological causes 
have not been confirmed. No disturbances have been found in follicle-stimulating 
hormone, luteinizing hormone, serum testosterone, prolactin, estradiol, and 
thyroid hormones in SSc patients [5, 11, 59, 60].
8. Diagnostic approach of erectile dysfunction
The diagnosis of erectile dysfunction in SSc patients is not always easy. We are 
following the common steps starting with taking a detailed history. Then assess-
ment with appropriate questionnaires and dynamic penile Duplex ultrasound is 
required. The ambiguity lies in the fact that penile vascular damage occurs in almost 
all SSc patients, regardless of clinical symptoms and the questionnaire results that 
often do not match with vascular findings. Thus, it is always better to carry out both 
investigations: the duplex ultrasound to document the degree of vascular involve-
ment and self-administered questionnaire. The International Index of Erectile 
Function is the standardized and most widely used tool for evaluating erectile dys-
function. As mentioned above, penile temperature in SSc patients is lower than in 
healthy individuals. Since cutaneous temperature depends on cutaneous blood flow 
and thermal exchanges with deeper tissues, these findings could suggest the pres-
ence of functional alterations of both tissue properties and blood flow. Therefore, 
assessing changes in thermal properties and temperature control processes of the 
penis in SSc patients could provide a potential clue in diagnosis of erectile dysfunc-
tion. It has to be noted that with the progression of micro/macrovascular damage in 
the natural course of the disease, a concomitant penile fibrosis and veno-occlusive 
dysfunction occur and usually lead to difficult-to-treat ED. We should pay atten-
tion in cases where the reduced blood flow is observed, for example, on the hands 
(Raynaud’s phenomenon), because it can suggest that the penile arterial flow will 
be also altered, and it may be a sign of initial stage of ED in SSc patients [61, 62].
9. Treatment and recommendation for erectile dysfunction
It is not a mistake to initiate ED treatment by eliminating general cardiovascular 
risk factors including lifestyle, psychological, or drug-related factors, but such 
treatment is often unsatisfactory. This step usually has beneficial effect on erectile 
function in the general population [63]. Phosphodiesterase-5 (PDE-5) inhibitors 
are recommended as a first-line option for pharmacotherapy. In non-SSc men, 
this group of drugs causes the relaxation of smooth muscle cells and temporarily 
increases arterial blood flow in the penis. However, to achieve an erection, sexual 
stimulation is required, because this class of drugs is not considered as an initiator 
of erection. Several types of PDE-5 inhibitors are currently available. The most 
commonly used are sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). 
Except these, newer molecules of PDE-5 inhibitors can be used, for example, 
mirodenafil, udenafil, and avanafil. All types of PDE-5 inhibitors are effective and 
safe regarding the treatment of ED in the normal population. The differences are 
only in their half-lives, when, for instance, tadalafil is effective for up to 36 hours 
whereas the effectiveness of sildenafil is only 12 hours. The choice of a PDE5-I 
depends on the frequency of intercourse and the patient’s personal experience  
[64, 65]. However, research on the efficacy of PDE-5 inhibitors is very limited in 
SSc patients [5]. Proietti et al. reported that once-daily tadalafil improved both 
erectile function and vascular measures of cavernous arteries in men with SSc-
related erectile dysfunction. Also, an increase in frequency of morning erections 
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and decrease in plasma ET1 levels were found. They suggest that daily tadalafil dose 
could play a potential role in preventing progression of penile fibrosis and erectile 
dysfunction in male SSc patients [58]. Furthermore, long-acting PDE-5 may lead to 
a decrease in the frequency and severity of Raynaud’s phenomenon and the promo-
tion of digital ulceration [66].
Patients who do not respond to PDE-5 inhibitors may be offered to try vacuum 
constriction devices. It was reported that patients who used the vacuum therapy 
system for a month to increase blood oxygenation in the corpora cavernosa and then 
employed the vacuum constriction device to maintain penile erection for sexual 
intercourse significantly improved their erectile function and sexual satisfaction 
[67]. However, there are no reports about the use of this system in patients with SSc.
Another option for the treatment of erectile dysfunction is prostaglandin 
analogues, which can be administered via intracavernous injections or intraurethral 
application. Alprostadil is a stable form of prostaglandin E1 that increases the 
concentration of cyclic adenosine monophosphate and decreases the intracellular 
calcium concentration, resulting in the relaxation of smooth muscle cells. Several 
studies reported the efficiency of alprostadil in the general population, but in terms 
of SSc patients, it was reported that a substantial percentage of SSc patients did not 
respond adequately to intracavernous prostaglandin E1 injections [68].
When pharmacotherapy fails and the patient wants a permanent solution, the 
surgical implantation of a penile prosthesis may be considered as the third-line 
option. Penile prosthesis improved erectile dysfunction in over 70% of men in 
the general population. Available prostheses are either malleable (semirigid) or 
inflatable (two or three pieces), but it should be considered that there are two 
main complications of penile prosthesis implantation—the mechanical failure and 
infection [5, 64, 65].
Most of the treatment options described above have not been verified in patients 
with systemic sclerosis yet. In spite of the fact that erectile dysfunction is common 
in men with systemic sclerosis, demographics, risk factors, and ED treatments have 
not been sufficiently investigated. Only a small case series has described unsatisfac-
tory results with on-demand sildenafil (25–50 mg). The higher dose of sildenafil has 
not been investigated. Tadalafil has been slightly better evaluated in the treatment 
of SSc-related erectile dysfunction. The efficiency of 20 mg tadalafil on demand 
and 20 mg tadalafil in a fixed alternate day regimen has been compared. The results 
showed that flow-mediated dilatation and peak systolic velocities of cavernous 
arteries at penile duplex ultrasound improved significantly with the alternate day 
treatment; but no significant changes were observed after the on-demand tadalafil 
dosing. In addition, the alternate day regimen also reduced the plasma levels of 
ET-1 and vascular cell adhesion molecule as markers of endothelial function [68]. 
Therefore, long-term administration of tadalafil and its constant plasma level seems 
to have a positive effect on the treatment of ED in male SSc patients.
10. Conclusion
Sexual dysfunction is a common problem in both men and women with systemic 
sclerosis. Erectile dysfunction is the dominant issue in males, which seems to be 
tightly linked to vascular dysfunction. Sexual dysfunction in the female patient is 
not less prevalent, but it is considerably more complex and it has been less studied. 
Several diagnostic approaches have been established to assess sexual dysfunction. 
Also, there are some treatment options available, but most of them have not been 
sufficiently verified in patients with systemic sclerosis. Further research regarding 
sexual dysfunction in patients with systemic sclerosis is strongly needed.
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